Epstein-Barr Virus: The Path from Association to Causality for a Ubiquitous Human Pathogen

PLoS Biology

Volumn 12, Issue 9, 2014, Pages

  Sugden, Bill ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 1; HLA ANTIGEN; RAIN; VIRUS DNA;

AFRICA; ALLELE; ANOPHELES; ANTIBODY TITER; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; ENVIRONMENTAL TEMPERATURE; EPSTEIN BARR VIRUS; GENETIC ASSOCIATION; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MALARIA; MULTIPLE SCLEROSIS; NASOPHARYNX CARCINOMA; NONHUMAN; RISK FACTOR; STOMACH CARCINOMA; VIRUS GENOME; VIRUS IDENTIFICATION; CELL CYCLE; COMPLICATION; EPSTEIN-BARR VIRUS INFECTIONS; EUROPE; GENETICS; MALARIA, FALCIPARUM; NASOPHARYNGEAL NEOPLASMS; PARASITOLOGY; PATHOGENICITY; PATHOLOGY; VIROLOGY; WESTERN HEMISPHERE;

HUMAN HERPESVIRUS 4;

AFRICA; AMERICAS; BURKITT LYMPHOMA; CELL CYCLE; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; EUROPE; HERPESVIRUS 4, HUMAN; HUMANS; MALARIA, FALCIPARUM; MULTIPLE SCLEROSIS; NASOPHARYNGEAL NEOPLASMS;

EID: 84920412197     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1001939     Document Type: Article

References (34)

1. Burkitt DP, (1983) The discovery of Burkitt's lymphoma. Cancer 51: 1777–1786.
2. Epstein MA, Achong BG, Barr YM, (1964) Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1: 702–703.
3. de-Thé G, Geser A, Day NE, Tukei PM, Williams EH, et al. (1978) Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 274: 756–761.
4. Geser A, de Thé G, Lenoir G, Day NE, Williams EH, (1982) Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma. Int J Cancer 29: 397–400.
5. Lam KM, Syed N, Whittle H, Crawford DH, (1991) Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet 337: 876–878.
6. Zur Hausen H, Schulte-Holthausen H, (1970) Presence of EB virus nucleic acid homology in a “virus-free” line of Burkitt tumour cells. Nature 227: 245–248.
7. Moss DJ, Pope JH, (1972) Assay of the infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol 17: 233–236.
8. Manolov G, Manolova Y, (1972) Marker band in one chromosome 14 from Burkitt lymphomas. Nature 237: 33–34.
9. Taub R, Kirsch I, Morton C, Lenoir G, Swan D, et al. (1982) Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci U S A 79: 7837–7841.
10. Nanbo A, Sugden A, Sugden B, (2007) The coupling of synthesis and partitioning of EBV's plasmid replicon is revealed in live cells. EMBO J 26: 4252–4262.
11. Vereide DT, Sugden B, (2011) Lymphomas differ in their dependence on Epstein-Barr virus. Blood 117: 1977–1985.
12. Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, et al. (2010) Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 115: 925–935.
13. Henle G, Henle W, (1976) Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 17: 1–7.
14. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, et al. (1985) Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 36: 545–547.
15. Simons MJ, Wee GB, Day NE, Morris PJ, Shanmugaratnam K, et al. (1974) Immunogenetic aspects of nasopharyngeal carcinoma: I. Differences in HL-A antigen profiles between patients and control groups. Int J Cancer 13: 122–134.
16. Su W-H, Hildesheim A, Chang Y-S, (2013) Human Leukocyte Antigens and Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: Old Associations Offer New Clues into the Role of Immunity in Infection-Associated Cancers. Front Oncol 3: 299.
17. Klein G, Giovanella BC, Lindahl T, Fialkow PJ, Singh S, et al. (1974) Direct evidence for the presence of Epstein-Barr virus DNA and nuclear antigen in malignant epithelial cells from patients with poorly differentiated carcinoma of the nasopharynx. Proc Natl Acad Sci U S A 71: 4737–4741.
18. Kaschka-Dierich C, Adams A, Lindahl T, Bornkamm GW, Bjursell G, et al. (1976) Intracellular forms of Epstein-Barr virus DNA in human tumour cells in vivo. Nature 260: 302–306.
19. Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, et al. (2010) Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. J Immunother 33: 983–990.
20. Küppers R, Rajewsky K, Zhao M, Simons G, Laumann R, et al. (1994) Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A 91: 10962–10966.
21. Mancao C, Hammerschmidt W, (2007) Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 110: 3715–3721.
22. Kimura H, Ito Y, Kawabe S, Gotoh K, Takahashi Y, et al. (2012) EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 119: 673–686.
23. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, et al. (1994) Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A 91: 9131–9135.
24. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, et al. (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789.
25. Iwakiri D, Eizuru Y, Tokunaga M, Takada K, (2003) Autocrine growth of Epstein-Barr virus-positive gastric carcinoma cells mediated by an Epstein-Barr virus-encoded small RNA. Cancer Res 63: 7062–7067.
26. Kieff ED, Rickinson AB (2006) Epstein-Barr virus and its replication. In: Knipe DM, Howley PM, editors. Fields Virology, chapter 68A. Fifth edition. Philadelphia (Pennsylvania): Lippincott Williams & Wilkins. pp. 2603–2654.
27. Operskalski EA, Visscher BR, Malmgren RM, Detels R, (1989) A case-control study of multiple sclerosis. Neurology 39: 825–829.
28. Munger KL, Levin LI, O'Reilly EJ, Falk KI, Ascherio A, (2011) Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult Scler 17: 1185–1193.
29. Levin LI, Munger KL, O'Reilly EJ, Falk KI, Ascherio A, (2010) Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol 67: 824–830.
30. Sawcer S, Hellenthal G, Pirinen M, Spencer CCA, Patsopoulos NA, et al. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214–219.
31. Lünemann JD, Jelcić I, Roberts S, Lutterotti A, Tackenberg B, et al. (2008) EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-gamma and IL-2. J Exp Med 205: 1763–1773.
32. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T, (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2: 1288–1290.
33. Baxter R, Ray P, Tran TN, Black S, Shinefield HR, et al. (2013) Long-term effectiveness of varicella vaccine: a 14-Year, prospective cohort study. Pediatrics 131: e1389–96.
34. Cohen JI, Fauci AS, Varmus H, Nabel GJ, (2011) Epstein-Barr virus: an important vaccine target for cancer prevention. Sci Transl Med 3: 107fs7.